Streetbeat News

Analyst Ratings

MDGL

Oppenheimer analyst Jay Olson maintains an Outperform rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $320 to $375.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:27 pm

ANIP

Capital One analyst Timothy Chiang initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with an Overweight rating, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:27 pm

LEN

Oppenheimer analyst Tyler Batory has maintained a Perform rating on Lennar (NYSE:LEN), indicating no change in the investment firm's outlook on the company.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:25 pm

AQMS

Benchmark analyst Michael Legg initiates coverage on Aqua Metals (NASDAQ:AQMS) with a Speculative Buy rating and a price target of $2.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:25 pm

ADBE

Oppenheimer analyst Brian Schwartz has maintained an Outperform rating on Adobe (NASDAQ:ADBE) and kept the price target at $660.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:23 pm

PHR

Canaccord Genuity analyst Richard Close maintains a Buy rating on Phreesia (NYSE:PHR) and raises the price target from $36 to $37.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:22 pm

PATH

Canaccord Genuity analyst Kingsley Crane maintains a Buy rating on UiPath (NYSE:PATH) and raises the price target from $27 to $30.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:20 pm

MOMO

Benchmark analyst Fawne Jiang maintains a Buy rating on Hello Gr (NASDAQ:MOMO) but lowers the price target from $22 to $16.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:20 pm

RSG

Morgan Stanley analyst Toni Kaplan downgraded Republic Services (NYSE:RSG) from Overweight to Equal-Weight, indicating a neutral outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:19 pm

MDGL

Canaccord Genuity analyst Edward Nash maintains a Buy rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $338 to $377.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:16 pm